이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Dual-targeting of B & T Cell Pathways Evaluation Trial (DUET)

2026년 11월 12일 업데이트: Diabetes Free, Inc.

Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study

This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.

연구 개요

연구 유형

중재적

등록 (추정된)

72

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Male and female participants, age 18 years and older.
  • Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written informed consent.
  • Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
  • Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met.
  • Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months.
  • Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining autologous hematopoietic stem-cell transplantation
  • Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months

Exclusion Criteria:

  • Diagnosis of a non-rheumatic autoimmune disease requiring therapeutic or investigational immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months).
  • History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria).
  • Severe unresolved cardiac disease.
  • Estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2.
  • Presence or history of active infections, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded.
  • Acute infection requiring systemic therapy or hospitalization within 30 days before screening.
  • Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment.
  • Any history of malignancy in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin.
  • Primary or secondary immunodeficiency, including hypogammaglobulinemia.
  • History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders.
  • Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity reactions other than localized injection site reaction, to any biological molecule.
  • Systemic corticosteroid therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy.
  • Intolerance of or contraindication to oral or IV corticosteroids.
  • Treatment with other biologic or non-biologic immunosuppressant agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy.
  • The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery.
  • Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product.
  • Received any form of stem cell transplant.
  • Administration of live attenuated vaccine(s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice.
  • Plasmapheresis within 3 months prior to first dose of DFI205
  • Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective contraceptive measures for the duration of the study and 6 months after discontinuation.
  • Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Phase 1 Single Ascending Dose Escalation

Intravenous (IV) infusion of DFI205 at ascending dose levels.

A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

실험적: Phase 2a Multi-Dose

DFI205 monthly IV infusions at the recommended Phase 2 dose

A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
기간: Up to 1 year post-dosing

Numbers and types of all adverse events (AEs) and serious adverse events (SAEs)

Up to 1 year post-dosing
To monitor immune reconstitution after completion of dosing with DFI205
기간: Up to 1 year post-dosing

Time to normalized peripheral blood B cell counts compared to baseline.

Up to 1 year post-dosing
To monitor immune response to DFI205
기간: Up to 1 year post-dosing

Number of participants with anti-drug antibody development.

Up to 1 year post-dosing

2차 결과 측정

결과 측정
측정값 설명
기간
To evaluate the ability of DFI205 to induce an objective response in adults with RA
기간: 24 weeks post-dosing

Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP < 2.6, DAS28-ESR <2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
기간: 24 weeks post-dosing

Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
기간: 24 weeks post-dosing

Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of >5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline >10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
기간: 24 weeks post-dosing

Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60)

24 weeks post-dosing

기타 결과 측정

결과 측정
측정값 설명
기간
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
기간: 24 weeks post-dosing

Change in tender joint count (TJC28) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
기간: 24 weeks post-dosing

Change in swollen joint count (SJC28) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SLE
기간: 24 weeks post-dosing

Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SSc
기간: 24 weeks post-dosing

Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
기간: 24 weeks post-dosing

Change in creatine phosphokinase (CPK) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
기간: 24 weeks post-dosing

Change in muscle strength (MMT8 score) compared to baseline

24 weeks post-dosing
To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
기간: Up to 1 year post-dosing
Up to 1 year post-dosing
To investigate the pharmacokinetics of DFI205
기간: Up to 1 year post-dosing

Blood samples will be collected to quantitate serum concentrations of DFI205

Up to 1 year post-dosing
To investigate the pharmacodynamics of DFI205 in blood
기간: Up to 1 year post-dosing

Proportions of immune cell subsets in blood by FACS analysis over the course of the study.

Up to 1 year post-dosing
To investigate the secondary lymphoid system pharmacodynamics of DFI205
기간: Up to 1 year post-dosing

Proportions of disease-specific lymph node cell populations over the course of the study.

Up to 1 year post-dosing
To investigate soluble CD40 pharmacodynamics of DFI205
기간: Up to 1 year post-dosing

Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments.

Up to 1 year post-dosing

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Georg Schett, M.D., University of Erlangen-Nürnberg

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2028년 8월 1일

연구 완료 (추정된)

2028년 12월 1일

연구 등록 날짜

최초 제출

2026년 11월 3일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다